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Summary
Cytotoxic T lymphocyte antigen 4 (CTLA- 4) haploinsufficiency (CHAI) 
and lipopolysaccharide- responsive beige- like anchor (LRBA) deficiency 
(LATAIE) are newly identified inborn errors of immunity with shared 
molecular pathomechanisms and clinical manifestations. In this review, 
we aimed to provide differential comparisons regarding demographic, 
clinical, immunological and molecular characteristics between these two 
similar conditions. A literature search was conducted in PubMed, Web 
of Science and Scopus databases and included studies were systematically 
evaluated. Overall, 434 (222 CHAI and 212 LATAIE) patients were found 
in 101 eligible studies. The CHAI patients were mainly reported from 
North America and western Europe, while LATAIE patients were pre-
dominantly from Asian countries. In CHAI, positive familial history 
(P < 0·001) and in LATAIE, consanguineous parents (P < 0·001) were 
more common. In CHAI patients the rates of granulomas (P < 0·001), 
malignancies (P = 0·001), atopy (P = 0·001), cutaneous disorders (P < 0·001) 
and neurological (P = 0·002) disorders were higher, while LATAIE patients 
were more commonly complicated with life- threatening infections 
(P = 0·002), pneumonia (P = 0·006), ear, nose and throat disorders 
(P < 0·001), organomegaly (P = 0·023), autoimmune enteropathy 
(P = 0·038) and growth failure (P < 0·001). Normal lymphocyte subsets 
and immunoglobulins except low serum levels of CD9+ B cells (14·0 versus 
38·4%, P < 0·001), natural killer (NK) cells (21 versus 41·1%, P < 0·001), 
immunoglobulin (Ig)G (46·9 versus 41·1%, P = 0·291) and IgA (54·5 versus 
44·7%, P = 0·076) were found in the majority of CHAI and LATAIE 
patients, respectively. The most frequent biological immunosuppressive 
agents prescribed for CHAI and LATAIE patients were rituximab and 
abatacept, respectively. Further investigations into the best conditioning 
and treatment regimens pre- and post- transplantation are required to 
improve the survival rate of transplanted CHAI and LATAIE patients.
Keywords: CHAI, CTLA- 4, inborn errors of immunity, LATAIE, LRBA, 
primary immunodeficiency disease
Introduction
Inborn errors of immunity (IEIs) are a heterogeneous 
group of inherited disorders that affect the development 
and function of the immune system, and predispose patients 
to chronic susceptibility to recurrent infections, autoim-
mune disorders, allergy, lymphoproliferation and malig-
nancy. In the last decade, due to the increased availability 
of genome sequencing, the spectrum of IEIs with immune 
dysregulation phenotype is rapidly expanding [1].
It has also been shown that the underpinning molecular 
pathomechanisms of some of these monogenic disorders 
are greatly overlapping. For instance, disorders of the cyto-
toxic T lymphocyte- associated protein 4 (CTLA- 4) pathway, 
including autosomal dominant CTLA- 4 haploinsufficiency 
Clinical and Experimental Immunology REVIEW doi: 10.1111/cei.13600
M. Jamee et al.
© 2021 British Society for Immunology, Clinical and Experimental Immunology, 0: 2–162
with autoimmune infiltration (CHAI) and autosomal reces-
sive lipopolysaccharide- responsive beige- like anchor (LRBA) 
(LATAIE) deficiency with autoantibodies, regulatory T (Treg) 
cell defects, autoimmune infiltration and enteropathy dis-
eases, often present with similar clinical phenotypes due 
to their linked biology [2,3].
CTLA- 4 is an immune checkpoint molecule, primarily 
found on the surface of T cells [4]. In addition to direct 
tolerogenic effects, CTLA- 4 outcompetes CD28 for binding 
to their shared co- stimulatory ligands, CD80 and CD86, 
and removes them from antigen- presenting cells (APCs) 
via transendocytosis, thereby preventing continuous activa-
tion of T cells [5]. Although CTLA- 4 is induced upon T 
cell receptor (TCR) activation in conventional T cells, it 
is constitutively expressed on Treg cells and promotes their 
suppressive function [6]. CTLA- 4 is also involved in 
humoral immunity, as it regulates CD28- dependent fol-
licular helper T cell differentiation [7]. LRBA binds to 
the cytoplasmic tails of CTLA- 4 and prevents the traf-
ficking of CTLA- 4 to lysosomes and consequent degrada-
tion [8]. CHAI disease is predominantly characterized by 
lymphoproliferation, autoimmune cytopenia, enteropathy, 
interstitial lung disease and recurrent infections [9– 11]. 
LATAIE also generally presents with enteropathy, autoim-
munity, lymphoproliferation and respiratory infections 
[12– 14]. The immunological phenotype in both disorders 
includes hypogammaglobulinemia, progressive loss of B 
cells, an increase in CD21low B cells, and elevated T fol-
licular helper cells [15,16]; however, Treg cell counts are 
often normal in CHAI, in contrast to its reduced level 
in LATAIE [17,18].
Despite the fact that several kindreds have been reported 
in the literature, distinctions between these two groups 
of patients remain elusive. In this regard, we aimed to 
provide a systematic review of clinical, immunological and 
molecular characteristics of patients with CTLA- 4 haplo-
insufficiency and LRBA deficiency and also a differential 
comparison between these two similar conditions.
Methods
Search strategy, study selection and data extraction
We performed a systematic search of the PubMed, Web of 
Science and Scopus Library databases for articles published 
in peer- reviewed journals up to June 2020. The keywords 
used in our search strategy for patients with CTLA- 4 hap-
loinsufficiency were as follows: ‘cytotoxic T- lymphocyte- 
associated protein 4 haploinsufficiency’, ‘CTLA- 4 protein 
deficiency’, ‘CTLA- 4 haploinsufficiency’, ‘cytotoxic T- lymphocyte- 
associated protein 4 deficiency’, ‘CTLA- 4 haploinsufficiency 
with autoimmune infiltration’, ‘CHAI’, ‘CTLA- 4 immunode-
ficiency’ or ‘CTLA- 4 mutation’. In addition, the following 
search keywords were used for patients with LRBA deficiency: 
‘lipopolysaccharide- responsive beige- like anchor protein’, 
‘LPS- responsive beige- like anchor protein’, ‘LRBA’, regulatory 
T cell defects, autoimmune infiltration and enteropathy, 
‘LATAIE’, ‘LRBA deficiency’, ‘LRBA immunodeficiency’ or 
‘LRBA mutation’.
The search strategy is summarized in Supporting infor-
mation, Fig. S1. Manual screening for references from 
original articles and major reviews was performed to 
identify eligible studies. We adhered to the Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses 
(PRISMA) guidelines for performing the systematic review. 
The methods of screening and selection of eligible articles 
and extraction of data into an electronic database are 
described elsewhere in detail [19].
Statistical and genetic analysis
The statistical analyses were performed on a pooled sample 
of aggregate data derived from related studies. For this 
purpose, the overall extracted data of two subgroups were 
combined without weighting. Central and descriptive sta-
tistics were used for the interpretation of quantitative data. 
For variables with abnormal distribution, median and 
interquartile ranges (IQR) were calculated. For comparisons 
between two groups of patients, Mann– Whitney U, χ2 or 
Fisher’s exact tests were applied. All statistical tests were 
two- tailed, and a P- value of less than 0·05 was considered 
statistically significant. The statistical analyses were per-
formed using spss version 26.0 software (SPSS, Inc., Chicago, 
IL, USA).
For the genetic analysis we applied a uniform mutation 
nomenclature and, in some cases, we changed mutation 
numberings to conform to the Human Genome Variation 
Society (HGVS) guidelines. Wherever the mutation’s effect 
on the protein (except for splice site and long InDel muta-
tions) was not reported, the MutationTaster software (http://
www.mutat ionta ster.org) was used to predict amino acid 
changes.
Ethics approval
The study was approved by the Alborz University of Medical 




For CHAI, the literature search identified 562 articles; 258 
articles were duplicates and 265 were excluded through the 
initial title and abstract screening. Overall, 39 articles met 
the inclusion criteria and were subsequently selected for 
data extraction. For LATAIE, 37 new articles were found 
in the literature and 17 articles were eligible. The extracted 
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data were added to the database prepared for our previous 
systematic review of patients with LATAIE [12]. A total of 
503 patients were reported in these articles, and 434 patients 
remained for data analysis after the removal of duplicate 
cases. Further investigations of these 434 patients identified 
73 and 148 mutated genes causing CHAI and LATAIE 
phenotypes in 222 and 212 patients, respectively.
Epidemiological characteristics of CHAI and LATAIE 
patients
In this review, 434 patients including 222 CHAI patients 
(101 males, 103 females and 18 of unknown gender) and 
212 LATAIE patients (109 males, 96 females and seven 
of unknown gender) were evaluated.
Figure 1 represents the distribution of patients in dif-
ferent countries. The reported CHAI patients are mainly 
studied in North America and western Europe, while 
LATAIE patients have a wider distribution among Asian 
countries.
Family history of immunodeficiency was reported in 
54·7% (210 of 384) of the study population, and patients 
with CHAI had higher rates of positive family history 
compared with LATAIE [62·7% (138 of 220) versus 43·9% 
(72 of 164), P  <  0·001]. All except one of the CHAI 
patients were born to non- consanguineous parents, while 
74·9% (131 of 175) of patients with LATAIE had con-
sanguineous parents (P  <  0·001) (Table 1).
Among patients with LATAIE, higher rates of death 
were reported compared with patients with CHAI [21% 
(42 of 200) versus 13·6% (27 of 199), P =  0·05]. The 
reported reasons for death were somewhat variable but 
mainly consisted of sepsis, lymphoma and organ failure 
in patients with CHAI and also sepsis, respiratory failure 
and internal hemorrhage in LATAIE patients (Supporting 
information, Table S1).
At the time the patients were first reported in the ref-
erenced studies, most patients with CHAI were in their 
third decade of life at a median (IQR) age of 24·5 (17·2– 
45·0) years, while LATAIE patients were younger with a 
median (IQR) age of 11·6 (6– 18) years. In the same man-
ner, the age at the onset of symptoms in LATAIE patients 
[median (IQR)  =  1·7 (0·6– 4·0)] was much lower than 
that of CHAI patients [median (IQR) =  10·0 (6·0– 16·0), 
P  <  0·001]. The CHAI patients were diagnosed later in 
the course of disease, with a median (IQR) diagnostic 
delay of 11·0 (6·0– 19·0) years compared with 5·0 (2·0– 9·6) 
years in LATAIE patients, P  <  0·001.
In CHAI patients, the median (IQR) age at first auto-
immune manifestation was 6·5 (2·0– 16·0) years, while in 
LATAIE patients the first presentations of autoimmunity 
started at a median (IQR) age of 3·0 (1·3– 6·0) years 
(P =  0·003). Furthermore, infectious complications and 
lymphoproliferative disorders significantly tend to develop 
earlier in patients with LATAIE, compared with CHAI 
(P <  0·001) (Table 1).
Clinical spectrum of CHAI and LATAIE patients
The schematic comparison of significant clinical differences 
between CHAI and LATAIE is provided in Fig. 2. A large 
proportion of patients with CHAI and LATAIE patients 
initially presented with autoimmune disorders (43·0 versus 
31·0%, P =  0·047), respiratory manifestations (17·0 versus 
28%, P = 0·047) and protracted diarrhea (16·0 versus 29%, 
P =  0·021), respectively (Fig. 3).
Among patients with an established primary clinical 
diagnosis (n  =  259) (Fig. 4), most patients with CHAI 
were diagnosed initially with predominantly antibody defi-
ciency (PAD) (34·0%), autoimmunity (28·0%) and enter-
opathy (18·0%). In LATAIE, the first clinical diagnosis 
also included predominantly antibody deficiency (40·0%), 
autoimmunity (21·0%) and autoimmune lymphoprolifera-
tive syndrome (16·0%).
Autoimmune disorders were the most common com-
ponent of both CHAI and LATAIE syndromes, and 66·8% 
of the patients (290 of 343) had at least one autoimmunity 
(Table 2). Additionally, 47·7% (207 of 434) of patients 
suffered from two or more autoimmune disorders. The 
most common concurrent autoimmune diseases were auto-
immune cytopenia and autoimmune enteropathy in both 
CHAI (18 of 143, 12·5%) and LATAIE (39 of 147, 26·5%) 
groups, while the second most prevalent overlap was 
observed between autoimmune cytopenia and autoimmune 
cutaneous disorders (16 of 143, 11·2%) in CHAI and 
between autoimmune cytopenia and insulin- dependent 
diabetes mellitus (IDDM) (23 of 147, 15·6%) in LATAIE 
patients.
Autoimmune cytopenias, including immune thrombo-
cytopenic purpura, autoimmune hemolytic anemia and 
autoimmune neutropenia, were the most common autoim-
mune complications in CHAI [96 (67·6%)] and LATAIE 
patients [106 (70·2%), P =  0·408]. Furthermore, autoim-
mune gastrointestinal disorders [40 (29·2%) versus 61 
(40·9%), P = 0·038], autoimmune cutaneous disorders (e.g. 
vitiligo and/or alopecia) [31 (22·8%) versus 13 (8·7%), 
P =  0·001] were frequently reported. Among autoimmune 
endocrinopathies, IDDM [23 (10·8%) versus 39 (18·4%), 
P =  0·027], thyroiditis [29 (13·6%) versus 19 (9%), 
P = 0·130) and Addison disease [2 (0·9%) versus 1 (0·5%), 
P =  1·00] were the most common in CHAI and LATAIE 
patients, respectively. Other rare autoimmune manifesta-
tions, such as autoimmune arthritis, autoimmune hepatitis, 
vasculitis, autoimmune neurological disorders and autoim-
mune eye abnormalities in 15 (6.8%) CHAI patients and 
17 (8.0%) LATAIE patients were also reported.
Lymphoproliferative disorders were another common 
complication in both syndromes. The non- malignant 
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Fig. 1. The geographical distribution of reported cytotoxic T lymphocyte antigen 4 haploinsufficiency with autoimmune infiltration (CHAI) (a) and 
lipopolysaccharide- responsive beige- like anchor deficiency with autoantibodies, regulatory T cell defects, autoimmune infiltration and enteropathy 
(LATAIE) (b) patients. The reported CHAI patients are mainly studied in North America and western Europe, while LATAIE patients have a wider 
distribution among Asian countries.
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lymphoproliferation (including lymphadenopathy, spleno-
megaly and/or hepatomegaly) was more frequently reported 
in LATAIE (54 versus 43·2%, P =  0·023) while malignant 
lymphoproliferation was more common in CHAI (17·4 
versus 7·1%, P =  0·001). Granulomatous changes were 
reported more commonly in CHAI patients (21·1 versus 
8·0%, P <  0·001) and mainly affected lung and brain.
Enteropathy (41·1 versus 28·9%, P =  0·032) and failure 
to thrive (27·8 versus 7·5%, P  <  0·001) were both signifi-
cantly more prevalent among LATAIE compared with CHAI 
patients. Ear, nose and throat (ENT) disorders such as otitis 
media, rhinitis and tonsillitis were more prevalent among 
LATAIE patients (17 versus 4·2%, P  <  0·001) (Table 3). 
Skin disorders, including eczema (26·3%), psoriasis (19·0%), 
atopic dermatitis (20·9%), warts (10·0%), alopecia (10·9%) 
and vitiligo (11·8%) complicated 81 (38%) CHAI and 29 
(13·7%) LATAIE individuals (P < 0·001). Neurological mani-
festations such as seizure, neurodevelopmental delay and 
demyelinating disorders were more common in CHAI 
(23·9%) compared with LATAIE (12·3%) patients, P = 0·002.
Life- threatening infections including pneumonia, sepsis, 
meningitis and peritonitis were reported in 156 of all patients 
[63 (29·6%), CHAI versus 93 (43·9%) LATAIE, P =  0·002].
The most common viral microorganisms identified in 
CHAI and LATAIE patients were Epstein– Barr virus (EBV) 
spp. (13.1 versus 5.7%, P = 0.008), cytomegalovirus (CMV) 
(6.1 versus 10.8%, P =  0.079) and varicella- zoster virus 
(VZV) spp. (6.6 versus 1.9%, P =  0.016), respectively. The 
bacterial infections were mainly caused by Streptococcus 
aureus spp. (7·0 versus 2·4%, P =  0·023), Salmonella (3·8 
versus 0·9%, P =  0·105) and Mycobacterium tuberculosis 
spp. (1·9 versus 0·5%, P =  0·372) in CHAI and LATAIE 
patients, respectively. The most common fungal microor-
ganisms were Candida spp. (6.6 versus 7.5%, P =  0.695), 
and aspergillus (2·8 versus 4·2%, P =  0·425) in CHAI and 
LATAIE patients, respectively.
Immunological findings of CHAI and LATAIE 
patients
Table 4 represents the available quantitative immunological 
data of patients with CHAI and LATAIE syndrome. Overall, 
333 of 434 patients, including 143 CHAI and 190 LATAIE 
patients, had at least one immunological parameter avail-
able in the published data and were included in the analysis 
described below.
Total lymphocyte counts were lower than the normal 
range for age in 22 (15·4%) CHAI and 24 (12·6%) LATAIE 
patients (P = 0·471). The median absolute neutrophil count 
(cells/µl) was significantly lower in CHAI compared with 
LATAIE patients (1400 versus 3861, P =  0·034).
Low lymphocyte subsets including CD3+ [12 (8·4%) versus 
22 (11·6%), P = 0·342], CD4+ [19 (13·3%) versus 34 (17·9%), 
P =  0·255], CD8+ [14 (9·8%) versus 19 (10·0%), P =  0·949] 
and Treg [12 (8·4%) versus 23 (12·1%), P =  0·274] were 
reported in a proportion of CHAI and LATAIE patients, 
respectively. Also, low counts for CD19+ B cells [20 (14·0%) 
versus 73 (38·4%), P <  0·001] and natural killer (NK) cells 
[30 (21%) versus 78 (41·1%), P <  0·001] were found in the 
majority of CHAI and LATAIE patients, respectively.
Adjusted to the age- matched normal ranges, low levels 
of serum IgG [67 (46·9%) versus 78 (41·1%), P =  0·291], 
immunoglobulin (Ig)A [78 (54·5%) versus 85 (44·7%), 
Table 1. Demographic data of patients with CHAI and LATAIE syndrome
Parameters Total CHAI LATAIE P- value
Number of patients 434 222 212
Sex ratio, M/F (n = 409) 210/199 101/103 109/96 0·459
Family history of PID, % (n = 384) 210 (54·7) 138 (62·7) 72 (43·9)  < 0·001*
Consanguinity, % (n = 363) 132 (36·4) 1 (0·5) 131 (74·9)  < 0·001*
Dead, % (n = 399) 69 (17·3) 27 (13·6) 42 (21) 0·05
Current age, years, median (IQR) (n = 382) 18 (10– 30) 24·5 (17·2– 45) 11·6 (6– 18)  < 0·001*
Age at onset, years median (IQR), (n = 275) 4 (1– 10) 10 (6– 16) 1·7 (0·6– 4)  < 0·001*
Age at diagnosis, years, median (IQR), (n = 220) 15·5 (8– 25·5) 23 (17– 40) 8 (5– 13)  < 0·001*
Delay in diagnosis, years, median (IQR), (n = 195) 7 (4– 15) 11 (6– 19) 5 (2– 9·6)  < 0·001*
Age at presentation of first autoimmunity, years, median (IQR) (n = 111) 4 (1·8– 7) 6·5 (2– 16) 3 (1·3– 6) 0·003*
Age at presentation of infection, years, median (IQR) (n = 65) 3 (1·25– 8) 12·5 (6·5– 24) 2 (1– 5)  < 0·001*
Age at presentation of allergy, years, median (IQR) (n = 12) 4·5 (2– 11·5) 12·5 (3– ) 4·5 (1·6– 8·5) 0·485
Age at presentation of lymphoproliferative disorder, years, median (IQR) (n = 45) 6 (3– 12) 17 (12– 33) 4 (3– 7)  < 0·001*
Age at presentation of malignancy, years, median (IQR) (n = 23) 28 (17– 42) 29 (17– 42·7) 2·3 0·087
M = male; F = female; n = count; PID = primary immunodeficiency disorders; IQR = interquartile range; CHAI = cytotoxic T lymphocyte antigen 4 
haploinsufficiency with autoimmune infiltration; LATAIE = lipopolysaccharide- responsive beige- like anchor deficiency with autoantibodies, regulatory 
T cell defects, autoimmune infiltration and enteropathy.
The median is shown (with 25th and 75th percentiles).
The statistically significant correlations are indicated in bold.
*P- value is statistically significant < 0·05. 
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P = 0·076], IgM [49 (34·3%) versus 53 (27·9%), P = 0·212] 
and IgE [8 (5·6%) versus 5 (2·6%), P = 0·167] were observed 
in CHAI and LATAIE patients, respectively.
Autoantibodies detected in patients are listed in Table 5. 
The most frequently detected autoantibodies in CHAI and 
LATAIE patients tested for autoantibodies were anti- nuclear 
antibodies (ANA) (39·3%) and anti- erythrocyte antibodies 
(36·8%), respectively.
Molecular findings of CHAI and LATAIE patients
CHAI and LATAIE disease are caused by loss- of- function 
mutations in CTLA- 4 and LRBA genes, respectively. The 
human CTLA- 4 gene (OMIM: *123890) is located on the 
chromosome position 2q33.2. It contains four coding exons 
that encode a 223- amino acid protein, CTLA- 4. There are 
73 distinct mutations among 222 patients (124 families) 
suffering from CHAI, including 37 (50·7%) missense, 14 
(19·2%) insertion/deletion frameshift, 10 (13·7%) nonsense, 
eight (11%) splice- site, three (4·1%) large insertion/dele-
tion and one (1·4%) start codon mutation. Among patients 
diagnosed with CHAI, the mutation has not been reported 
for four patients [20– 23]. To find a better estimation of 
penetrance we restricted our assessment to families with 
available mutation analyses in the proband and family 
members (at least parents). Among all 160 subjects of 42 
unrelated families (88 female and 72 male), 97 affected 
carriers and 63 unaffected carriers were identified, sug-
gesting a clinical penetrance of at least 60·6%. Interestingly, 
Fig. 2. Significant clinical differences between cytotoxic T lymphocyte antigen 4 haploinsufficiency with autoimmune infiltration (CHAI) and 
lipopolysaccharide- responsive beige- like anchor deficiency with autoantibodies, regulatory T cell defects, autoimmune infiltration and enteropathy 
(LATAIE) patients. In CHAI patients the rates of granulomas, malignancies, atopy, cutaneous disorders and neurological disorders are higher, while 
LATAIE patients are more commonly complicated with life- threatening infections, pneumonia, ear, nose and throat disorders, organomegaly, 
autoimmune enteropathy and growth failure.
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the extracellular (Ig) V- like domain had a large proportion 
(66·9%) of the mutations and the leader (signal peptide) 
domain and transmembrane domains each had 7·3% of 
the mutations. So far, no mutation has been identified in 
the intracellular (cytoplasmic tail, exon 4) domain (Fig. 5). 
Analysis of the correlation between the type of mutations 
and clinical and laboratory data demonstrated that 
enteropathy is more frequent in patients with a missense 
mutation (84·6%) than patients with nonsense or inser-
tion/deletion frameshift mutations (15·6%, P  =  0·028).
The human LRBA gene (OMIM: *606453) is located 
on the chromosome position 4q31.3. It contains one non- 
coding and 57 coding exons that encode a large 2863- 
amino acid protein, LRBA. Among the 212 LATAIE patients 
Fig. 3. The first presentations of cytotoxic T lymphocyte antigen 4 haploinsufficiency with autoimmune infiltration (CHAI) (a) and 
lipopolysaccharide- responsive beige- like anchor deficiency with autoantibodies, regulatory T cell defects, autoimmune infiltration and enteropathy 
(LATAIE) (b). Autoimmunity has been observed as the first presentation in most patients.
M. Jamee et al.
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(166 families) identified in our study, 183 (86·3%) patients 
(in 33 families) had homozygous mutations, 27 (12·7%) 
patients (in eight families) had compound heterozygous 
LRBA mutations, and for four patients the mutations were 
not reported [24– 27]. Monoallelic (heterozygous) mutations 
were reported in two patients [28]. Overall, 141 unique 
mutations were detected. These mutations consisted of 33 
missense (23·4%), 36 nonsense (25·5%), 18 splice- site 
(12·8%), 44 insertion/deletion frameshift (31·2%) and 10 
large insertion/deletion (7·1%) mutations. Mutations of the 
LRBA gene were located throughout the gene and no 
mutational hot- spot was observed (Fig. 5). The correlation 
analysis of mutation types with clinical and laboratory 
data showed that polyautoimmunity was more frequent 
Fig. 4. Distribution of available initial clinical diagnoses given to 259 patients with cytotoxic T lymphocyte antigen 4 haploinsufficiency with 
autoimmune infiltration (CHAI) (a) and lipopolysaccharide- responsive beige- like anchor deficiency with autoantibodies, regulatory T cell defects, 
autoimmune infiltration and enteropathy (LATAIE) (b) at the presentation. Patients are often diagnosed with predominantly antibody deficiencies. 
PAD = predominantly antibody deficiency; CVID = common variable immunodeficiency; CID = combined immune deficiency; ALPS = autoimmune 
lymphoproliferative syndrome; IPEX = immune dysregulation polyendocrinopathy enteropathy X- linked; HIES = hyper IgE syndrome; 
HIGM = hyper immunoglobulin (Ig)M syndrome; IPF = idiopathic pulmonary fibrosis.
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in patients with nonsense and insertion/deletion mutations 
(P =  0·015) in comparison to missense mutations.
The therapeutic approach in CHAI and LATAIE 
patients
The immunosuppressive treatment for autoimmune and/
or inflammatory complications mainly consisted of systemic 
corticosteroids in combination with biological agents (139 
of 298, 46·6%).
Targeted immunosuppressive therapy was applied in 189 
of 298 (63.4%) patients [63 (70·8%) CHAI and 126 (60·3%) 
LATAIE patients]. As illustrated in Fig. 6, CHAI patients 
were mainly treated with rituximab (n  =  24, 38·1%), 
abatacept (n  =  15, 23·8%) and other agents (n  =  16, 
25·4%), such as cyclophosphamide, adalimumab, etc. 
LATAIE patients mainly received abatacept (n = 60, 47·6%), 
sirolimus (n  =  35, 27·8%), cyclosporin (n  =  35, 27·8%) 
and mycophenolate mofetil (n = 34, 27·0%). Other immu-
nosuppressive agents, including azathioprine (n  =  30, 
15·9%), tacrolimus (n = 20, 10·6%), methotrexate (n = 13, 
6·9%) and anti- tumor necrosis factor (TNF) alpha (n = 12, 
6·3%), were also variably used in both groups.
Table 2. Autoimmune disorders in CHAI and LATAIE syndrome
Autoimmunity Total (n = 290) CHAI (n = 141) LATAIE (n = 149) P- value
Autoimmune endocrinopathy (%) 91 (31·9) 39 (28·9) 62 (41·1) 0·260
Autoimmune enteropathy (%) 101 (35·3) 39 (28·9) 62 (41·1) 0·038*
Autoimmune cytopenia (%) 202 (68·9) 96 (67·6) 106 (70·2) 0·408
Autoimmune skin disorders (%) 44 (15·4) 30 (22·4) 14 (9·3) 0·001*
Others (%) 32 (11) 13 (9·2) 19 (12·7) 0·832
The statistically significant correlations are indicated in bold.
CHAI  =  cytotoxic T lymphocyte antigen 4 haploinsufficiency with autoimmune infiltration; LATAIE  =  lipopolysaccharide- responsive  beige- like 
anchor deficiency with autoantibodies, regulatory T cell defects, autoimmune infiltration and enteropathy.
* P- value is statistically significant < 0·05. 
Table 3. Clinical manifestations of patients with CHAI and LATAIE syndrome
Parameters Total (n = 434) CHAI (n = 222) LATAIE (n = 212) P- value
Pneumonia (%) 141 (33·2) 56 (26·3) 85 (40·1) 0·006*
Sinusitis (%) 53 (12·2) 20 (9·4) 33 (15·6) 0·054
Ear, nose and throat disorders (%) 45 (10·6) 9 (4·2) 36 (17)  < 0·001*
Bronchiectasis (%) 56 (13·2) 24 (11·3) 32 (15·1) 0·244
Asthma and allergy (%) 68 (16) 47 (22·1) 21 (9·9) 0·001*
Interstitial lung disease (%) 84 (19·8) 49 (23) 35 (16·5) 0·093
Granulomas (%) 62 (14·6) 45 (21·1) 17 (8)  < 0·001*
Diarrhea (%) 203 (47·7) 106 (50) 97 (45·3) 0·330
Failure to thrive (%) 75 (17·6) 16 (7·5) 59 (27·8)  < 0·001*
Clubbing (%) 26 (6·1) 1 (0·5) 25 (11·8)  < 0·001*
Hepatobiliary disorders (%) 46 (10·8) 24 (11·3) 22 (10·4) 0·768
Organomegaly (%) 207 (48·7) 92 (43·2) 115 (54·2) 0·023*
Hematological disorders (%) 219 (50·6) 103 (46·6) 116 (54·7) 0·092
Malignancy (%) 52 (12·2) 37 (17·4) 15 (7·1) 0·001*
Autoimmunity (%) 290 (66·8) 143 (64·4) 147 (69·3) 0·276
Rheumatological disorders (%) 71 (16·7) 35 (16·4) 36 (17) 0·879
Skin disorders (%) 110 (25·9) 81 (38) 29 (13·7)  < 0·001*
Endocrine disorders (%) 111 (26·1) 52 (24·4) 59 (27·8) 0·423
Neurological/learning disorders (%) 77 (18·1) 51 (23·9) 26 (12·3) 0·002*
Meningitis (%) 7 (1·6) 2 (0·9) 5 (2·4) 0·284
Cardiovascular disorders (%) 22 (5·2) 16 (7·5) 6 (2·8) 0·029*
Renal disorders (%) 41 (9·6) 21 (9·9) 20 (9·7) 0·882
Abscess (%) 13 (3·1) 2 (0·9) 11 (5·2) 0·011*
Osteomyelitis (%) 2 (0·5) 1 (0·5) 1 (0·5) 1·000
Sepsis (%) 31 (7·3) 17 (8) 14 (6·6) 0·585
The statistically significant correlations are indicated in bold.
CHAI = cytotoxic T lymphocyte antigen 4 haploinsufficiency with autoimmune infiltration; LATAIE = lipopolysaccharide- responsive beige- like an-
chor deficiency with autoantibodies, regulatory T cell defects, autoimmune infiltration and enteropathy.
* P- value is statistically significant < 0·05. 
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Fifty- four (12·7%) patients, including 21 CHAI and 33 
LATAIE patients, underwent hematopoietic stem cell trans-
plantation (HSCT). The detailed HSCT characteristics were 
available in 48 (17 CHAI and 31 LATAIE) patients and 
summarized in Supporting information, Table S2. Patients 
with CHAI received transplantation at a median (IQR) 
age of 17·0 (14·0– 22·0) years, while patients with LATAIE 
were transplanted at a median (IQR) age of 10·0 (7·0– 
13·0) years (P < 0·001). Acute or chronic graft- versus- host 
disease (GvHD) was encountered in 20 of 48 (41·6%) 
patients. In addition, 26 of 48 (54·1%) patients developed 
other complications, mainly including CMV reactivation 
(n  =  14, 29·1%), adenovirus infection (n  =  8, 16·6%) and 
autoimmune flare (n  =  9, 18·7%). Reduced- intensity or 
myeloablative conditioning regimen mainly consisted of 
fludarabine (n = 46), busulfan (n = 16), treosulfan (n = 16), 
thiotepa (n  =  13), melphalan (n  =  11) and alemtuzumab 
(n  =  9) in various combinations.
Most patients (83·3%) received human leukocyte antigen 
(HLA)- identical transplants from a matched unrelated 
donor (MUD) (n  =  20, 41·6%), matched sibling donor 
(MSD) (n  =  10, 20·8%) or matched family donor (MFD) 
(n  =  10, 20·8%). Patients were followed- up at a median 
(IQR) time- period of 0·9 (0·3– 2·6) years, which did not 
differ between the two groups (P =  0·659). One LATAIE 
patient experienced graft failure before achieving full 
engraftment, 37 (77·1%) patients showed complete remis-
sion at first transplantation and 10 (20·8%) patients died 
at a median (IQR) age of 12·6 (9·8– 17·1). The overall 
survival rate in LATAIE was lower than in CHAI 
(P =  0.031) patients. The transplantation was associated 
with lower survival in both groups, although it was not 
statistically significant (P =  0·639) (Supporting informa-
tion, Fig. S2). Transplanted versus non- transplanted patients 
were reported to have a considerably more complicated 
pretransplant clinical status (i.e. life- threatening infections, 
malignancy or polyautoimmunity) (P =  0·002).
Discussion
LRBA deficiency and CTLA- 4 haploinsufficiency are newly 
identified inborn errors of immunity with shared clinical 
presentations. LRBA has a crucial role in CTLA- 4 regula-
tion and most of the patients with LATAIE reported having 
defects in CTLA- 4 expression; therefore, mutations in these 
two genes seem to be a phenocopy of each other [29]. 
In this study, we systematically reviewed and compared 
the clinical, immunological and molecular characteristics 
in these two similar conditions.
Table 4. Immunological profile of patients with CHAI and LATAIE syndrome
Parameters Total (n = 434) CHAI (n = 222) LATAIE (n = 212) P- value
WBC × 103 (cell/ul), median (IQR) (n = 69) 6200 (4500– 8715) 5000 (2350– 8242) 6200 (4800– 8900) 0·121
Absolute lymphocyte count × 103 (cells/µl), median (IQR) (n = 102) 2275 (1252– 3157) 1248 (651·5– 1543·5) 2385 (1350– 3450) 0·004*
Absolute neutrophil count × 103 (cells/µl), median (IQR) (n = 81) 3700 (1554– 6000) 1400 (484– 3684·5) 3861 (2006·2– 6081) 0·009*
CD3+ T cells × 103 (cell/μl), median (IQR) (n = 136) 1518 (917– 2074) 855·5 (614·5– 1326·5) 1696·5 (1142– 2187·5)  < 0·001*
CD4+ T cells × 103 (cell/μl), median (IQR) (n = 125) 672 (397– 1113) 450 (278·8– 594·7) 732 (440– 1150) 0·016*
CD8+ T cells × 103 (cell/μl), median (IQR) (n = 127) 625 (314– 1032) 219 (112– 492) 681 (418– 1081)  < 0·001*
CD4+/CD8+ ratio, (n = 131) 1·9 (1·5– 3·6) 1·9 (1·5– 3·6) – - 
NK cell, (cell/μl), median (IQR) (n = 133) 552 (296– 919) 100 (28– 376) 570 (323·7– 950·7) 0·001*
CD19+ B cells (cell/μl), median (IQR) (n = 142) 165·5 (30– 349) 80·5 (11·2– 243) 172 (44·7– 407·5) 0·045*
IgG, mg/dl, median (IQR) (n = 165) 542 (324·5– 943·5) 490 (316– 937) 570 (323·7– 950·7) 0·427
IgA (mg/dl), median (IQR) (n = 155) 40 (10– 79·4) 47·5 (23– 121) 29·0 (7·0– 73·5) 0·033*
IgM (mg/dl), median (IQR) (n = 156) 56 (26·2– 121·7) 57·9 (25– 99·5) 55·1 (27– 135) 0·589
IgE (IU/ml), median (IQR) (n = 53) 3 (1– 16) 11·9 (3– 34·2) 1·9 (0·3– 6·3) 0·016*
The statistically significant correlations are indicated in bold.
Ig  =  immunoglobulin; WBC  =  white blood cell; NK  =  natural killer; IQR  =  interquartile range; CHAI  =  cytotoxic T lymphocyte antigen 4 
haploinsufficiency with autoimmune infiltration; LATAIE = lipopolysaccharide- responsive beige- like anchor deficiency with autoantibodies, regulatory 
T cell defects, autoimmune infiltration and enteropathy.
* P- value is statistically significant < 0·05. 
Table 5. Autoantibodies found in patients with CHAI and LATAIE
Autoantibodies CHAI (%) LATAIE (%)
Coombs antibody 6 (20) 28 (41·8)
Anti- nuclear antibody 12 (40) 10 (14·9)
Anti- phospholipid antibody 2 (6·7) 5 (7·5)
Anti- smooth muscle antibody 2 (6·7) 1 (1·5)
Anti- neutrophil cytoplasmic antibody 2 (7·1) 3 (4·3)
Anti- thyroid peroxidase antibody 3 (10) 11 (16·4)
Anti- thyroglobulin antibody 1 (3·3) 5 (7·5)
Anti- glutamic acid decarboxylase 
antibody
5 (16·7) 4 (6)
Anti- insulin/anti- islet cell antibody 2 (6·7) 6 (8·9)
CHAI = cytotoxic T lymphocyte antigen 4 haploinsufficiency with au-
toimmune infiltration; LATAIE = lipopolysaccharide- responsive beige- 
like anchor deficiency with autoantibodies, regulatory T cell defects, 
autoimmune infiltration and enteropathy.
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In CHAI patients, positive familial history and in LATAIE 
consanguineous parents were more common. This may 
be due in part to the pattern of inheritance and geo-
graphical distribution of the two disorders. CHAI is inher-
ited in an autosomal dominant manner, and because of 
the lower penetrance can be inherited across generations, 
while LATAIE is an autosomal recessive disorder and most 
patients (86·3%) are homozygous for the mutation; thus, 
the two pathogenic alleles often come from two carrier 
parents from the same family and region.
Despite similarities in clinical manifestations, life- 
threatening infections are considerably more frequent in 
LATAIE patients. They are also more prone to lung infec-
tions and autoimmune enteropathy with associated failure 
to thrive. However, in CHAI individuals, granulomas, 
malignancies, atopies and autoimmune skin disorders are 
more common. Although the reason for higher rates of 
granuloma formation and malignancies in CHAI patients 
is unknown, it is proposed that chronic immune activation 
in CHAI may favor the occurrence of lymphoma and 
gastric cancer, and LATAIE patients either die or are cured 
with HSCT prior to establishing such complications [29]. 
An alternative hypothesis is that, as CHAI shows incom-
plete penetrance, disease development may be dependent 
Fig. 5. Graphic illustration of lipopolysaccharide- responsive beige- like anchor (LRBA) and cytotoxic T lymphocyte antigen 4 (CTLA- 4) protein 
domains with locations of published genetic mutations in CTLA- 4 haploinsufficiency with autoimmune infiltration (CHAI) and lipopolysaccharide- 
responsive beige- like anchor deficiency with autoantibodies, regulatory T cell defects, autoimmune infiltration and enteropathy (LATAIE) patients.  
(a) The 10 reported large deletions/duplications (exons 1– 2, 1– 22, 1– 30, 3– 15, 3– 37, 18– 30, 29– 30, 35, 41 and 49– 53) are not displayed in the figure. 
Mutations in LRBA occurred throughout the length of the gene, without hot- spots. (b) The three reported large deletions (2q33- 2q34del, 2q33.1- 
2q34del and 2q33.2- 2q33.3del) are not displayed in the figure. The disease- causative mutations in CTLA- 4 occur throughout the full- length gene, 
although the majority of mutations resided within the extracellular domain. Introns that interrupted codons are marked in red. Amino acids are 
designated by their single letter code. Domain and features positions recruited from UniProt database (https://www.unipr ot.org/).
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upon a ‘trigger’, such as infection with EBV, CMV, human 
papillomavirus (HPV) or Helicobacter pylori that initiates 
the immune dysregulation and/or lymphoproliferative dis-
ease. These pathogens are more likely to cause a chronic 
infection that would exacerbate immune responses, poten-
tially provoking lymphoproliferative disease as well as the 
eventual development of malignancy.
Autoimmune disorders, mainly autoimmune cytopenias, 
were the most common manifestation in both CHAI and 
LATAIE patients. In this respect, previous studies have 
introduced CTLA- 4 and LRBA as genes to be searched 
for mutations in pediatric cytopenias [30,31]. However, 
in the last decade, the spectrum of IEIs with autoimmune 
features have been expanding, making the diagnosis more 
complicated. For instance, patients with DEF6 deficiency 
exhibit early- onset autoimmunity/inflammation mainly in 
hematological and gastrointestinal systems, lymphoprolif-
eration and susceptibility to EBV infection [32]. In the 
immunological evaluation, T cell lymphopenia, low class- 
switched B cells and reduced CTLA- 4 expression in memory 
Treg cells are detected; however, as opposed to CHAI and 
LATAIE, obvious T cell exhaustion is not usually present 
[33]. Another example is the presentation of the autoim-
mune lymphoproliferative syndrome (ALPS)- like pheno-
type by LATAIE patients [26,34– 36]. In this review, 22 
(15.6%) LATAIE patients were initially diagnosed with 
ALPS. Although elevation in double- negative T (DNT) 
cells classically favors the diagnosis of ALPS, most of these 
22 patients had high levels of DNT cells. Therefore, inves-
tigation for other validate laboratory- based criteria such 
as defective lymphocyte apoptosis and elevated plasma 
sFASL, interleukin (IL)- 10, IL- 18 or vitamin B12 levels 
may help to achieve an accurate diagnosis [37].
Currently, there is no clinically available diagnostic 
laboratory test for distinguishing these two conditions. At 
the molecular level, higher CTLA- 4 expression in stimu-
lated T cells, enhanced sensitivity to lysosomal blocking 
agents and more efficient ligand uptake in LATAIE com-
pared with CHAI have been proposed [38]. However, 
LATAIE can generally be determined by the loss of LRBA 
protein expression. In the genetic evaluation, similar to 
previous studies [10,39– 41] the correlation between phe-
notype and genotype in CHAI and LATAIE patients was 
not clear and clinical characteristics were heterogeneous, 
suggesting the impact of the exposome, modifier genes 
and epigenetic mechanisms on the phenotype manifesta-
tion [12]. Residual expression and function in CHAI and 
LATAIE patients may, to some extent, explain the clinical 
heterogeneity between patients with different mutations; 
however, there is not enough data to verify this claim 
[17,42]. Mutations in LRBA were located throughout the 
gene; however, in CTLA4 mutations were mainly 
Fig. 5. (Continued)
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accumulated in the extracellular domain, and no mutation 
was found in the cytoplasmic domain (exon 4). Despite 
all, we demonstrated that in patients with LATAIE, inser-
tion/deletion frameshift or nonsense mutations (severe 
mutations) were associated with polyautoimmunity, and 
in the CHAI patients the missense mutations were cor-
related with enteropathy. In this regard, determining the 
association of clinical and laboratory phenotypes with 
genetic features would help to prepare an algorithm to 
ease the diagnosis and management of CHAI and LATAIE 
[10,26].
LATAIE shows nearly complete penetrance, whereas 
CHAI has an estimated 60·6% penetrance, which means 
that more than one- third of individuals with CTLA- 4 muta-
tions are asymptomatic. Accordingly, 39·4% of individuals 
with CTLA- 4 mutation had no clinical manifestations and 
were considered unaffected carriers. Recent studies reported 
a penetrance of around 67– 71% in CTLA- 4 insufficiency 
[10,29,43]. The lower estimated penetrance in this review 
may be due to the assessment of only CTLA- 4 insufficiency 
families with known mutation status in family members 
(at least in parents) of patients. Furthermore, some indi-
viduals with CTLA- 4 mutations had no obvious clinical 
manifestations, referred to as carriers. Despite high rates 
of penetrance in LATAIE, there are well- documented LRBA- 
mutated individuals, usually siblings of index cases, with 
no LRBA protein expression and no manifestations of 
disease. However, it would be reasonable to carefully moni-
tor both asymptomatic LATAIE and CHAI patients, as 
they may eventually manifest milder or less common fea-
tures of the disease (e.g. malignancy).
It seems that CTLA- 4 compared with LRBA mutations 
lead to a milder phenotype in humans. At the cellular 
level, this can partly be explained by the lower CTLA- 4 
level in memory Tregs of LATAIE than those of CHAI 
patients [38]. Another clue for the higher disease severity 
Fig. 6. The application of biologic immunosuppressive agents for the treatment of cytotoxic T lymphocyte antigen 4 haploinsufficiency with 
autoimmune infiltration (CHAI) and lipopolysaccharide- responsive beige- like anchor deficiency with autoantibodies, regulatory T cell defects, 
autoimmune infiltration and enteropathy (LATAIE) patients. Rituximab for CHAI patients and abatacept for LATAIE patients were the most frequent 
agents prescribed.
M. Jamee et al.
© 2021 British Society for Immunology, Clinical and Experimental Immunology, 0: 14–1614
with LRBA mutations is provided by the fact that the 
age of onset and diagnosis of the disease is significantly 
lower in LATAIE compared to CHAI patients, and the 
overall survival in LATAIE is lower than CHAI patients. 
These observations may further emphasize a higher need 
for timely vigilant management of LATAIE compared to 
CHAI patients.
Monoclonal antibody- based immunotherapies were 
widely utilized among CHAI and LATAIE patients. 
Abatacept, a soluble CTLA- 4 fusion protein, has been 
shown to significantly decrease disease activity in CHAI 
and LATAIE patients [8,25,35,44] and with other con-
ventional therapies may also be considered as a bridging 
therapy before HSCT. However, the degree to which CHAI 
and LATAIE patients are going to benefit from HSCT 
is obscure. In this study, transplanted versus non- 
transplanted patients had lower survival in both CHAI 
(P = 0·033) and LATAIE (P = 0·113) groups, which might 
be attributed to the more complicated pretransplant clini-
cal status (i.e. life- threatening infections, malignancy or 
polyautoimmunity) (P = 0·002). In the same way, a recent 
study reported a relatively high mortality rate (29.2%) 
in transplanted LATAIE patients [25]. For CHAI, there 
is little information regarding the application of HSCT; 
however, due to the underlying autoinflammation, they 
are suggested to receive strict immunosuppression and 
prophylaxis for GvHD before and after transplantation 
[45]. These data are somewhat inconclusive for choosing 
the best therapeutic option, mainly because of the recent 
application of HSCT in such disorders and the lack of 
detailed transplantation data available in the literature. 
To improve HSCT survival, further studies are required 
to determine which subset of CHAI and LATAIE patients 
benefit most from transplantation and reach a consensus 
to candidate eligible patients for HSCT before they become 
critically ill.
In summary, despite similarities in the clinical picture, 
the manifestations in patients with LATAIE commence at 
earlier ages and are more acute and life- threatening in 
nature, while in patients with CHAI, signs and symptoms 
take more time to develop and disease has lower penetrance, 
thus leading to longer survival and greater generational 
inheritance. Currently, both CHAI and LATAIE patients 
are responsive to immunosuppression with steroids and 
biological drugs. HSCT has not been associated with a 
significant improvement in the survival of CHAI and 
LATAIE patients. Further prospective investigations into 
the best conditioning and treatment regimens pre- and 
post- HSCT may be required to improve the survival rate 
of transplanted CHAI and LATAIE patients. In order to 
achieve earlier diagnosis and prevent further complications, 
it would be appropriate to look for an underlying CTLA- 4 
or LRBA gene mutation in patients with an initial PAD 
diagnosis and predominant autoimmune complications.
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Supporting Information
Additional supporting information may be found in the on-
line version of this article at the publisher’s web site:
Fig. S1. Flowchart of the systematic search and study selec-
tion process for CTLA4 Haploinsufficiency (A) and LRBA 
deficiency (B).
Fig. S2. Kaplan Meier’s Survival Plots. The overall survival 
in both groups is evaluated and differences among survival 
curves are assessed by the log- rank test; A) CHAI patients 
stratified whether or not they underwent HSCT, P = 0.033, 
B) LATAIE patients stratified whether or not they under-
went HSCT, P = 0.113, C) The overall survival in CHAI and 
LATAIE patients is compared, P  =  0.031, D) Transplanted 
CHAI vs. LATAIE patients are compared, P = 0.639.
Table S1. Causes of death (where stated).
Table S2. Summary of available data on hsct characteristics 
among patients with chai and lataie syndromes.
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